(1) See Appendix for reconciliation of GAAP and non-GAAP operating income (loss), net income (loss) and basic and diluted income (loss) per share.
Summary Comments
Commenting on the company’s progress in 2020, Dr. Graves said, “With our singular focus on additive manufacturing, we were pleased to deliver strong growth at the end of what was an unprecedented year. The execution of our four-stage plan to deliver increased value to our customers and shareholders, initiated in the summer of 2020, took hold and rapidly gained momentum as we moved through the second half of the year. By the fourth quarter, the results of these efforts in our two focused businesses became very clear. Our Healthcare business delivered exceptional revenue growth of 48% year-over-year, driven strongly by both dental and medical applications, while also making a significant technological breakthrough in our emerging regenerative medicine area, which will be increasingly important to our Healthcare business in the years ahead. We were also very pleased with our Industrial performance during the fourth quarter, which recorded double-digit revenue growth on a consecutive quarter basis, continuing the recovery we have seen in our markets from the effects of the COVID-19 pandemic. Our Industrial business growth reflected broad-based wins, particularly in the metals application areas, pointing to increasing demand for our products in markets like aerospace, automotive, and consumer products.